Rising Autoimmune Disorders Fueling The Growth Of The Market Due To Increasing Demand For Symptom Management And Complication Prevention: Pivotal Factor Influencing Raynauds Disease Treatment Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Raynauds Disease Treatment Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size of Raynaud's disease treatment has witnessed significant growth. Projected growth from $1.39 billion in 2024 to $1.49 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%, is due to certain key factors. The progression observed in the past can be linked to heightened cognizance of autoimmune conditions, advanced diagnostic technologies, wider utilization of calcium channel inhibitors, a rise in connective tissue conditions, and an upswing in the elderly population.

How Will the Raynauds Disease Treatment Market Size Evolve and Grow by 2029?
In the upcoming years, the market size of treatment for Raynaud's disease is predicted to experience hardy growth. The market is set to escalate to $1.98 billion in 2029 with a compound annual growth rate (CAGR) of 7.4%. This growth in the forecasted period can be ascribed to the increased use of telehealth for vascular consults, proliferation of personalized medicine, heightened research regarding endothelial dysfunction, growing frequency due to extreme climatic conditions, and the expansion in healthcare infrastructure. Significant trends for the forecast period encompass the incorporation of Artificial Intelligence in preliminary diagnosis and disease tracking, progress in digital thermal monitoring devices, creation of targeted biologics, enhancements in cell therapy and gene editing, and the rise of telemedicine and digital health technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/raynauds-disease-treatment-global-market-report

What Drivers Are Propelling the Growth of Raynauds Disease Treatment Market Forward?
The escalation in autoimmune disease cases is expected to spur the expansion of the raynauds disease treatment market. Autoimmune diseases are conditions where the body's immune system erroneously targets healthy tissues, resulting in inflammation and damage. This increase in his disease type is due to people living in increasingly urbanized and sterile environments, which reduce immune system training and coupled with modern lifestyle factors like poor diet, stress and pollution. Treatment for Raynaud's disease aids the management of autoimmune diseases by enabling improved management of symptoms, reducing tissue damage and preventing complications from hindered blood circulation. For instance, according to a June 2024 report by the Australian Institute of Health and Welfare, a governmental organization based in Australia, the hospitalizations for rheumatoid arthritis in 2021-22 were 10,000. This was a 25% increase from the preceding year's 8,000, equating to a rate of 39 hospitalizations per 100,000 population. As a result, the heightened occurrence of autoimmune diseases is increasing the growth potential of the raynauds disease treatment market. Robust health expenditure is seen as a driving factor in the growth of the raynauds disease treatment market due to better access and improved care. Health-related expenditure refers to the overall money spent on medical services, treatments, and health resources within a specific duration. As the elderly population increases, there's a substantial rise in health expenditure due to amplified demand for medical services, long-term care, and age-related treatments, putting immense financial pressure on healthcare systems. Health expenditure benefits Raynaud's disease treatment by facilitating better access to medicines, advanced diagnostics, specialist care, funding new therapies research and public awareness programs that effectively manage symptoms. Also, in April 2025, the American Medical Association, a professional association based in the U.S, reported that in 2023, there was a 7.5% increase in health spending, reaching a total of $4.9 trillion, or $14,570 per individual. This was a noticeable increase in comparison with the 4.6% growth seen in 2022. Consequently, the robust health expenditure is seen as a growth stimulator for the raynauds disease treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24680&type=smp

Which Emerging Trends Are Transforming the Raynauds Disease Treatment Market in 2025?
Leading enterprises in the raynauds disease treatment market are concentrating on creating inventive solutions for combating raynauds disease, like oral calcium channel blockers which enhance blood flow through relaxing and expanding blood vessels, subsequently decreasing the occurrence and intensity of vasospastic attacks. Oral calcium channel blockers are a category of medicine ingested orally that aid in relaxing and enlarging blood vessels by stopping the influx of calcium into the muscle cells of the heart and blood vessel walls. For example, in June 2023, Aisa Pharma Inc., a clinical-stage biopharmaceutical entity based in the US, initiated the second phase of its Phase 2b RECONNOITER trial to examine Profervia (cilnidipine), an oral calcium channel blocker, for the treatment of raynaud's phenomenon in individuals with systemic sclerosis (SSc). This was after encouraging outcomes from the first phase, where Profervia indicated a higher decrease in the attack frequency of raynaud's and SSc disease severity than other calcium channel blockers, while also displaying a positive safety profile and good tolerance. The trial, which is advancing with a 20 mg dose, seeks to meet the critical demand for efficient treatments for Raynaud's in SSc, a situation that currently does not have approved treatments.

What Are the Key Segments in the Raynauds Disease Treatment Market?
The raynauds disease treatment market covered in this report is segmented -

1) By Treatment Type: Medication, Thermal Therapies, Surgical Procedures, Alteative Therapies
2) By Drug Class: Calcium Channel Blockers, Vasodilators, Antiplatelet Agents
3) By Route of Administration: Oral, Topical, Injectable, Intravenous
4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Pharmacies

Subsegments:
1) By Medication: Calcium Channel Blockers, Alpha Blockers, Vasodilators, Topical Nitrates, Selective Serotonin Reuptake Inhibitors (SSRIs), Phosphodiesterase Inhibitors, Angiotensin Receptor Blockers (ARBs)
2) By Thermal Therapies: Hand Warmers, Thermal Gloves, Heated Pads, Biofeedback-Controlled Thermal Devices
3) By Surgical Procedures: Sympathectomy, Nerve Decompression Surgery, Vascular Surgery
4) By Alternative Therapies: Acupuncture, Biofeedback Therapy, Herbal Remedies, Nutritional Supplements, Stress Management Techniques

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24680&type=smp

Who Are the Key Players Shaping the Raynauds Disease Treatment Market's Competitive Landscape?
Major companies operating in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., Concert Pharmaceuticals Inc.

What Geographic Markets Are Powering Growth in the Raynauds Disease Treatment Market?
North America was the largest region in the raynauds disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the raynauds disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24680

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.